The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Sarcoidosis is a rare inflammatory disease that causes the formation of granulomas—small lumps or nodules. Although it primarily affects the lungs, it can involve multiple organs, including the…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Approximately 20% of Western patients with nonsquamous non-small-cell lung cancer (NSCLC) present with EGFR mutations, creating a market for targeted and personalized treatments. Although the…
Approximately 20% of Western patients with nonsquamous non-small-cell lung cancer (NSCLC) present with EGFR mutations, creating a market for targeted and personalized treatments. Although the…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche /…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…